LeMaitre Vascular Inc (LMAT), Boston Scientific Corporation (BSX) – The Race In Medical Device Industry: Who Is The Winner?

Boston Scientific Corporation (NYSE:BSX) is now able to offer a full portfolio of bradycardia and heart failure devices after it recently launched a family of pacemakers. These pacemakers monitor respiration, adjust its pace accordingly and provide insight into the patient’s overall heart failure status. These devices contain radio frequency technology which improves the efficiency of the device. This new technology automatically sends the patient’s health information to the physician.

Boston Scientific Corporation (NYSE:BSX) also made its first Votalio pacemaker implant in June 2013. The pacemaker features a technology which helps the physicians identify patients suffering from severe sleep apnea, a disease which if left untreated may lead to fatal diseases. Through this acquisition and the recent initiative launches, Boston now has a competitive edge over its competitors. These activities will also help the company expand its customer base and earn huge profits in the coming years.

Conclusion

Both companies have a lot of growth potential and will be able to grab a larger market share. The strategies adopted by LeMaitre and Boston will help them increase their foothold in the industry. LeMaitre Vascular Inc (NASDAQ:LMAT) currently has a stable financial position as its profits and per share earnings have been increasing over the years. Therefore, I am declaring LeMaitre a winner and making a buy recommendation for this stock.

Despite being the industry leader and the first mover in many of its segments, Boston Scientific Corporation (NYSE:BSX) has a weak financial position. The company has been incurring huge losses. Its new launches and acquisition will help the company in recovering from this dark phase but it will take some time. Hence, I would not recommend this stock for short term investors.

The article The Race In Medical Device Industry: Who Is The Winner? originally appeared on Fool.com and is written by usman iftikhar.

usman iftikhar has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. usman is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.